Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Rocuronium bromide 50mg/5ml solution for injection ampoules
1501050X0AAAEAE
|
Rocuronium bromide | Rocuronium bromide | Anaesthesia | No data available |
|
Rocuronium bromide 50mg/5ml solution for injection vials
1501050X0AAACAC
|
Rocuronium bromide | Rocuronium bromide | Anaesthesia | No data available |
|
Rodomel XL 150mg capsules
0403040W0BCABAE
|
Rodomel | Venlafaxine | Central Nervous System | No data available |
|
Rofecoxib 12.5mg tablets
1001010AFAAACAC
|
Rofecoxib | Rofecoxib | Musculoskeletal and Joint Diseases | No data available |
|
Rofecoxib 12.5mg/5ml oral suspension sugar free
1001010AFAAAAAA
|
Rofecoxib | Rofecoxib | Musculoskeletal and Joint Diseases | No data available |
|
Rofecoxib 25mg tablets
1001010AFAAADAD
|
Rofecoxib | Rofecoxib | Musculoskeletal and Joint Diseases | No data available |
|
Rofecoxib 25mg/5ml oral suspension sugar free
1001010AFAAABAB
|
Rofecoxib | Rofecoxib | Musculoskeletal and Joint Diseases | No data available |
|
Rofecoxib 50mg tablets
1001010AFAAAEAE
|
Rofecoxib | Rofecoxib | Musculoskeletal and Joint Diseases | No data available |
|
Roferon-A 18million units/0.5ml inj pre-filled syringes
0802040J0BCAQBG
|
Roferon-A | Interferon alpha | Malignant Disease and Immunosuppression | No data available |
|
Roferon-A 18million units/0.6ml inj cartridges
0802040J0BCAPBF
|
Roferon-A | Interferon alpha | Malignant Disease and Immunosuppression | No data available |
|
Roferon-A 3million units/0.5ml inj pre-filled syringes
0802040J0BCAJAV
|
Roferon-A | Interferon alpha | Malignant Disease and Immunosuppression | No data available |
|
Roferon-A 4.5million units/0.5ml inj pre-filled syringes
0802040J0BCAKAW
|
Roferon-A | Interferon alpha | Malignant Disease and Immunosuppression | No data available |
|
Roferon-A 6million units/0.5ml inj pre-filled syringes
0802040J0BCALAX
|
Roferon-A | Interferon alpha | Malignant Disease and Immunosuppression | No data available |
|
Roferon-A 9million units/0.5ml inj pre-filled syringes
0802040J0BCAMAY
|
Roferon-A | Interferon alpha | Malignant Disease and Immunosuppression | No data available |
|
Rogitine 10mg/1ml solution for injection ampoules
0205040P0BBAAAA
|
Rogitine | Phentolamine mesilate | Cardiovascular System | No data available |
|
Rohto Dry Eye Relief 0.2% eye drops
21300000147
|
Rohto Dry Eye Relief 0.2% eye drops | Eye Products | Appliances | No data available |
|
Rohto Dry Eye Relief 0.2% eye drops 0.5ml unit dose
21300000148
|
Rohto Dry Eye Relief 0.2% eye drops 0.5ml unit dose | Eye Products | Appliances | No data available |
|
Rohypnol 1mg tablets
0401010I0BBAAAA
|
Rohypnol | Flunitrazepam | Central Nervous System | No data available |
|
Rolapitant 90mg tablets
0406000AHAAAAAA
|
Rolapitant | Rolapitant | Central Nervous System | No data available |
|
Roletra 10mg tablets
0304010D0BHAAAA
|
Roletra | Loratadine | Respiratory System | No data available |
|
Romiplostim 125microgram inj vials
0901040B0AAACAC
|
Romiplostim | Romiplostim | Nutrition and Blood | No data available |
|
Romiplostim 250microgram inj vials
0901040B0AAAAAA
|
Romiplostim | Romiplostim | Nutrition and Blood | No data available |
|
Romiplostim 250microgram powder and solvent inj vials
0901040B0AAABAB
|
Romiplostim | Romiplostim | Nutrition and Blood | No data available |
|
Rommix 250 EC tablets
0501050C0BIAAAB
|
Rommix (Tablet) | Erythromycin | Infections | No data available |
|
Romosozumab 105mg/1.17ml inj pre-filled disposable devices
0606020AAAAAAAA
|
Romosozumab | Romosozumab | Endocrine System | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.